PT  - JOURNAL ARTICLE
AU  - Roberto Rabinovich
AU  - Bruce Millar
AU  - Karolina Wrobel
AU  - Gourag Chaudhury
AU  - Kareshma Ranjit
AU  - Ellen Drost
AU  - Lisa Edwards
AU  - David Lomas
AU  - Stephen Rennard
AU  - Alvar Agusti
AU  - Ruth Tal-Singer
AU  - Jørgen Vestbo
AU  - Emiel Wouters
AU  - Edwin J.R. Van Beek
AU  - John Murchison
AU  - William MacNee
AU  - Jeffrey Huang
TI  - Circulating desmosine relates to cardiovascular comorbidity, coronary artery calcification score (CACS), systemic inflammation and mortality in patients with COPD
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P2028
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P2028.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P2028.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - IntroductionCOPD is a risk factor for cardiovascular comorbidities. Elastin degradation represents a shared mechanism for the pulmonary and vascular features.Methods and resultsPlasma desmosine (pDES), a marker of elastin degradation, was measured in 955 COPD patients (609 male, age 63.1±7.2 years, FEV1 50.6±15.1 %predicted) by an isotope dilution LC-MS/MS method. Coronary artery calcification (CACS), a surrogate of atherosclerosis, was assessed in 440 standard CT scan images (low <100 Agatston units [AU]), intermediate (101–400 AU), high (401–1000 AU) or very high (>1000 AU).ResultspDES was elevated in patients with cardiovascular comorbidities (p<0.01) and correlated with FEV1 (r=0.39, p<0.0001), MMRC (r=0.16, p<0.0001), 6MWD (r=-0.16, p<0.0001), BODE index (r=0.10, p<0.005), fibrinogen, IL6, IL8, CCL18, and SPD but not with emphysema . These variables showed significant higher values in the patients in the highest pDES quartile. pDES was elevated in patients with very high CACS in comparison with patients with lower CACS and in patients that died during a 3 year follow-up (p<0.0001).ConclusionpDES relates to lung function, systemic inflammation, cardiovascular comorbidities, and CACS in patients with COPD. pDES is a predictor of all cause overall mortality.The ECLIPSE study (GSK Study No. SCO104960, NCT00292552) was sponsored by GlaxoSmithKline.